Johnson & Johnson Reports Strong Q3 2026 Results: Accelerated Growth and Impact Ahead
Johnson & Johnson (JNJ) has reported a strong third quarter for 2026, with operational sales growth of 6% ahead of analyst consensus. This performance reinforces the company's confidence in meeting its guidance and exceeding $100 billion in annual revenue for the first time in its 140-year history.
The company's Chairman and CEO, Joaquin Duato, highlighted the strong performance in the third quarter as a key driver of growth and impact for Johnson & Johnson. With six strategic focus areas, including oncology, immunology, neuroscience, cardiovascular surgery, and vision, the company is leading in areas of higher medical need where innovation can make the greatest difference for patients.
Johnson & Johnson's powerful combination of innovative medicine and MedTech expertise strengthens its competitiveness. The company now has 29 products and platforms that generate at least $1 billion in annual sales, with many showing strong traction and growth. Notably, eight brands within the innovative medicine portfolio delivered double-digit growth in the third quarter.
In oncology, Johnson & Johnson is making significant progress to redefine cancer care from treatment to cure. The company's oncology business grew approximately 17% in the third quarter, driven by strong sales of multiple myeloma therapies and combination regimens. In particular, TECVAYLI plus TALVEY demonstrated a 89% reduction in the risk of disease progression or death as early as the second line of treatment.
The company is also seeing rapid growth in solid tumors, with RYBREVANT sales increasing by 64%. Johnson & Johnson expects to receive U.S. FDA approval for RYBREVANT FASPRO in advanced head and neck cancer later this year, which would address a significant unmet need in the market.
In bladder cancer, INLEXZO has emerged as a market leader just one year after its launch, with nearly one in three eligible patients starting on an INLEXZO regimen in the third quarter. This demonstrates the growing role of INLEXZO in transforming care for high-risk, non-muscle invasive disease.
Johnson & Johnson's sales performance in the third quarter exceeded $25 billion, putting the company on track to meet its guidance and achieve a major milestone in exceeding $100 billion in annual revenue. With a clear path to double-digit growth by the end of the decade, Johnson & Johnson is poised for continued success and innovation.
